{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.5","upperLimit":"60.9","value":"41.9"},{"groupId":"OG001","lowerLimit":"23.5","upperLimit":"61.1","value":"41.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"This is the best overall response as measured by Clinical response. Clinical response is defined as having complete remission (CR), bone marrow complete remission (BM-CR), partial remission or hematologic improvement (HI) as defined by the International Working Group (IWG) response criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"NUMBER","populationDescription":"Full analysis set: Consisted of all patients who were randomized to one of the two treatment arms","reportingStatus":"POSTED","timeFrame":"48 months","title":"Clinical Response Other Than Composite Clinical Response for Myeloid Dysplastic Syndromes(MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Per Investigator (Phase Llb)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}